Business briefs: Gilead, Bristol-Myers Squibb and GlaxoSmithKline

Share this article:

A two-year study of HIV drug regimens shows Gilead's Striblid quad pill edges out three-part Atripla in virus suppression, with 84% of quad pill patients reaching undetectable levels compared with viral suppression of 82% of patients on Atripla, which is co-marketed by Gilead and Bristol-Myers Squibb, reports Medpage Today. The findings showed similar efficacy among patients younger than 40 and older than 40, and across sexes and ethnic backgrounds.

GlaxoSmithKline submitted an sNDA to the FDA so its BRAF inhibitor dabrafenib and MEK inhibitor trametinib can be paired up to treat metastatic melanoma. GSK submitted sNDAs for each of the drugs so they can be used in a two-for-one setting. Phase II studies comparing dabrafenib monotherapy vs. combination treatment are the basis of the proposal. The drug maker's oncology efforts also include its recent deal with the British biotech Immunocore. The deal focuses on developing ImmTACs to treat cancers and viral diseases. The deal gives $181 million to Immunocore now, with the promise of up to $255 million in additional milestone payments.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.